0001448431
false
0001448431
2023-11-06
2023-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 6, 2023
OptimizeRx Corporation
(Exact name of registrant as specified in charter)
Nevada |
|
001-38543 |
|
26-1265381 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
260 Charles Street, Suite 302, Waltham, MA |
|
02453 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 248.651.6568
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 Par Value |
|
OPRX |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
On November 6, 2023, OptimizeRx Corporation issued
a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished
with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 and Exhibit
99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information
be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
OPTIMIZERX CORPORATION |
|
|
|
Date: November 6, 2023 |
By: |
/s/ Edward Stelmakh |
|
Name: |
Edward Stelmakh |
|
Title: |
Chief Financial Officer |
2
Exhibit 99.1
OptimizeRx Reports Third Quarter 2023 Financial Results
- Increases guidance for 2023 and introduces guidance for 2024
- Total revenue of $16.3 million
- GAAP net loss per share of $(0.17)
- Non-GAAP net income per share of $0.09
- Total DAAP (fka RWD) deals for the year now stands at 16
- Completed acquisition of Medicx Health after quarter end
WALTHAM, Mass. – November 6, 2023
– OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping
life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30,
2023. Quarterly comparisons are to the same year-ago period.
Financial Highlights
| ● | Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 million in the
same year ago period. |
| ● | Gross profit in the third quarter of 2023 increased 4% year-over-year to $9.8 million, from $9.4 million
during the third quarter of 2022. |
| ● | GAAP net loss totaled $(2.9) million or $(0.17) per basic and diluted shares outstanding in the third
quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022. |
| ● | Non-GAAP net income in the third quarter totaled $1.6 million or $0.09 per fully diluted shares outstanding,
as compared to $1.3 million or $0.07 per fully diluted shares outstanding during the third quarter of 2022 (see definition of this non-GAAP
measure and reconciliation to GAAP, below). |
| ● | Adjusted EBITDA for the third quarter of 2023 came in at $0.9 million compared to $1.0 million
in the same year ago period (see definition of this non-GAAP measure and reconciliation to GAAP, below). |
| ● | Cash, cash equivalents and short-term investments
totaled $63.5 million as of September 30, 2023 as compared to $74.1 million as of December 31, 2022 |
Will Febbo, OptimizeRx CEO commented, “I
am excited to announce third quarter results came in well above expectations. We’ve seen significant momentum build up since the start
of the second half of 2023, particularly around the utilization of our Dynamic Audience Activation Platform (DAAP). In fact, our total
number of deals for the year is tracking ahead of expectations and now stands at 16. The macro headwinds we’ve been highlighting since
the middle of last year have seemed to normalize and large pharma that started initial pilot programs with companies that had newly entered
the space are now completing the measurement of these programs and, as we expected, have learned that these solutions are not scalable
and are beginning to drive spend back our way.”
“As a result, we couldn’t have asked for
better timing to complete the acquisition of Medicx Health. Both business lines are showing growth, profitability, and are seeing significant
client engagement. We are also moving forward as planned on executing against the numerous revenue, technological and operational synergies
we identified. On a combined basis, revenues are expected to quickly surpass $100 million over the next 12 months while generating profitability
and cash flow. The transaction further expands our omnichannel reach beyond HCPs to patients while adding multiple channels we haven’t
accessed previously. The ability to provide significant scale for pharma manufacturers is quickly moving us up the decision maker hierarchy
within our larger customers.”
“Given that backdrop, I’m happy to say, we’re
increasing our guidance for 2023 and are now looking for revenue and adjusted EBITDA to come in between $68-$70 million and $3-$4 million,
respectively, for the year. We expect OptimizeRx’s pre-acquisition business will account for $63 to $65 million of 2023’s revenue guidance,
which is up from our previous guidance which called for revenue to be in the mid-50 to low-60 million dollar range. We’re also introducing
preliminary 2024 guidance and expect revenue to be at least $110 million and expect adjusted EBITDA margins to be at least 10%.”
Key Performance Indicators (KPIs)* |
|
Rolling
Twelve Months
Ended
September 30,
2023 |
|
|
Rolling
Twelve Months
Ended
June 30,
2023 |
|
Average revenue per top 20 pharmaceutical manufacturer |
|
$ |
2,075,078 |
|
|
$ |
1,972,308 |
|
Percent of top 20 pharmaceutical manufacturers that are customers |
|
|
90 |
% |
|
|
90 |
% |
Top 20 pharmaceutical manufacturers as percent of total net revenues |
|
|
59 |
% |
|
|
58 |
% |
Net revenue retention |
|
|
93 |
% |
|
|
89 |
% |
Revenue per averages full-time employee (FTE) |
|
$ |
570,973 |
|
|
$ |
559,646 |
|
2023 Financial Outlook
Based on OptimizeRx’s results for the first nine
months of 2023 and its recent acquisition, the Company is updating its full year financial outlook for 2023. Revenues for 2023 are now
expected to be between $68 million and $70 million and we expect our adjusted EBITDA to come in between $3 million and $4 million.
The Company is introducing preliminary 2024 guidance
at this time and expects revenue to be at least $110 million with an adjusted EBITDA margin of at least 10%.
Conference Call
Date: |
Monday, November 6, 2023 |
|
Time: |
8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) |
|
Toll Free: |
1-877-423-9813 |
International: |
1-201-689-8573 |
Conference ID: |
13742267 |
Call Me Link: https://callme.viavid.com/viavid/?callme=true&passcode=13742267&h=true&info=company-email&r=true&B=6
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1640427&tp_key=4d243008bb.
Definition and Use of Non-GAAP Financial Measures
This earnings release includes a
presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share or non-GAAP EPS, Adjusted EBITDA and
Adjusted EBITDA margin, all of which are non-GAAP financial measures.
The Company defines non-GAAP net income
(loss) as GAAP net income (loss) with an adjustment to add back depreciation, amortization, stock-based compensation, acquisition
expenses, severance expense related to a reduction in force, income or loss related to the fair value of contingent consideration,
and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares
outstanding on a diluted basis. Adjusted EBITDA is defined as GAAP net income (loss) with an adjustment to add back depreciation,
amortization, interest, stock-based compensation, acquisition expenses, severance expense related to a reduction in force, income or
loss related to the fair value of contingent consideration, and deferred income taxes. Adjusted EBITDA margin is defined as Adjusted
EBITDA divided by revenue. The Company has provided non-GAAP financial measures to aid investors in better understanding its
performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow
of the Company.
Because of varying available valuation methodologies,
subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management
believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s
core business operating results and those of other companies, as well as provides an important tool for financial and operational decision
making and for evaluating the Company’s own core business operating results over different periods of time.
The Company’s non-GAAP financial
measures may not provide information that is directly comparable to that provided by other companies in the Company’s
industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP
net income (loss), non-GAAP EPS, Adjusted EBITDA and Adjusted EBITDA margin are not measurements of financial performance under GAAP
and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure
of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or
superior to the information provided by its GAAP financial results.
The table, “Reconciliation of GAAP to NON-GAAP
Financial Measures,” included below, provides a reconciliation of non-GAAP net income (loss), non-GAAP EPS, and Adjusted EBITDA
for the three and nine months ended September 30, 2023 and 2022. Although the Company provides guidance for Adjusted EBITDA and
Adjusted EBITDA margin, it is not able to provide guidance to the most directly comparable GAAP measures. Reconciliations for forward-looking
figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain
components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, amortization
or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision
that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance
of the unavailable information.
Definition of Key Performance Indicators*
Top 20 pharmaceutical manufacturers: The
definition of “top 20 pharmaceutical manufacturers” is based upon Fierce Pharma’s list of “The top 20 pharma companies
by 2022 revenue”.
Net revenue retention: Net revenue retention
is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following
year (i.e., excludes new client relationships for the most recent year).
Revenue per average Full Time Employee:
We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of
employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount
at the end of the most recent.
About OptimizeRx
OptimizeRx provides best-in-class health technology
that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout
the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology
platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on
their medications.
For more information, follow the Company on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking
Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”,
“estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”,
“targets”, “designed”, “could”, “may”, “should”, “will” or other
similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s
expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking
statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected
revenues, expected Adjusted EBITDA, expected adjusted EBITDA margin and prospects. These forward-looking statements are based on the Company’s
current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims
any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events,
or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some
of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated
by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include,
but are not limited to, any synergies and other anticipated benefits of the Medicx merger may not be realized or may take longer than
anticipated to be realized; the risk that the integration of OptimizeRx and Medicx will be more costly or difficult than expected; the
effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
OPTIMIZERX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
ASSETS | |
| | |
| |
Current assets | |
| | |
| |
Cash and cash equivalents | |
$ | 9,921,475 | | |
$ | 18,208,685 | |
Short-term investments | |
| 53,620,576 | | |
| 55,931,821 | |
Accounts receivable, net | |
| 20,838,762 | | |
| 22,155,301 | |
Prepaid expenses and other | |
| 3,008,858 | | |
| 2,280,828 | |
Total current assets | |
| 87,389,671 | | |
| 98,576,635 | |
Property and equipment, net | |
| 149,304 | | |
| 137,448 | |
Other assets | |
| | | |
| | |
Goodwill | |
| 22,673,820 | | |
| 22,673,820 | |
Technology assets, net | |
| 7,548,337 | | |
| 7,702,895 | |
Patent rights, net | |
| 1,777,669 | | |
| 1,940,178 | |
Deferred financing costs | |
| 300,000 | | |
| — | |
Right of use assets, net | |
| 148,641 | | |
| 235,320 | |
Other intangible assets, net | |
| 3,141,709 | | |
| 3,384,889 | |
Other long-term assets | |
| 800,000 | | |
| — | |
Total other assets | |
| 36,390,176 | | |
| 35,937,102 | |
TOTAL ASSETS | |
$ | 123,929,152 | | |
$ | 134,651,185 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable – trade | |
| 691,159 | | |
| 1,549,979 | |
Accrued expenses | |
| 3,108,907 | | |
| 2,601,246 | |
Revenue share payable | |
| 3,685,390 | | |
| 3,990,440 | |
Current portion of lease liabilities | |
| 27,687 | | |
| 89,902 | |
Deferred revenue | |
| 188,394 | | |
| 164,309 | |
Total current liabilities | |
| 7,701,538 | | |
| 8,395,876 | |
Non-current liabilities | |
| | | |
| | |
Lease liabilities, net of current portion | |
| 120,955 | | |
| 144,532 | |
Total liabilities | |
| 7,822,493 | | |
| 8,540,408 | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2023 or December 31, 2022 | |
| — | | |
| — | |
Common stock, $0.001 par value, 166,666,667 shares authorized, 18,386,920 and 18,288,571 shares issued at September 30, 2023 and December 31, 2022, respectively | |
| 18,387 | | |
| 18,289 | |
Treasury stock, $0.001 par value, 1,741,397 and 1,214,398 shares held at September 30, 2023 and December 31, 2022, respectively | |
| (1,741 | ) | |
| (1,214 | ) |
Additional paid-in-capital | |
| 176,206,572 | | |
| 172,785,800 | |
Accumulated deficit | |
| (60,116,559 | ) | |
| (46,692,098 | ) |
Total stockholders’ equity | |
$ | 116,106,659 | | |
$ | 126,110,777 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 123,929,152 | | |
$ | 134,651,185 | |
The accompanying notes are an integral part of
these condensed consolidated financial statements.
OPTIMIZERX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Net revenue | |
$ | 16,331,484 | | |
$ | 15,085,504 | | |
$ | 43,152,560 | | |
$ | 42,795,699 | |
Cost of revenues, exclusive of depreciation and amortization presented separately below | |
| 6,531,183 | | |
| 5,664,733 | | |
| 18,093,949 | | |
| 16,283,307 | |
Gross profit | |
| 9,800,301 | | |
| 9,420,771 | | |
| 25,058,611 | | |
| 26,512,392 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
General and administrative expenses | |
| 12,887,083 | | |
| 12,661,703 | | |
| 39,161,752 | | |
| 36,373,298 | |
Depreciation, amortization and noncash lease expense | |
| 466,706 | | |
| 515,828 | | |
| 1,395,400 | | |
| 1,565,484 | |
Total operating expenses | |
| 13,353,789 | | |
| 13,177,530 | | |
| 40,557,152 | | |
| 37,938,782 | |
Loss from operations | |
| (3,553,487 | ) | |
| (3,756,759 | ) | |
| (15,498,541 | ) | |
| (11,426,390 | ) |
Other income | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 688,190 | | |
| 289,967 | | |
| 2,074,081 | | |
| 313,786 | |
Loss before provision for income taxes | |
| (2,865,297 | ) | |
| (3,466,792 | ) | |
| (13,424,460 | ) | |
| (11,112,604 | ) |
Income tax benefit | |
| — | | |
| — | | |
| — | | |
| — | |
Net loss | |
$ | (2,865,297 | ) | |
$ | (3,466,792 | ) | |
$ | (13,424,460 | ) | |
$ | (11,112,604 | ) |
Weighted average number of shares outstanding – basic | |
| 16,637,606 | | |
| 17,981,184 | | |
| 16,907,482 | | |
| 17,994,288 | |
Weighted average number of shares outstanding – diluted | |
| 16,637,606 | | |
| 17,981,184 | | |
| 16,907,482 | | |
| 17,994,288 | |
Loss per share – basic | |
$ | (0.17 | ) | |
$ | (0.19 | ) | |
$ | (0.79 | ) | |
$ | (0.62 | ) |
Loss per share – diluted | |
$ | (0.17 | ) | |
$ | (0.19 | ) | |
$ | (0.79 | ) | |
$ | (0.62 | ) |
The accompanying notes are an integral part of
these condensed consolidated financial statements.
OPTIMIZERX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
For the Nine Months
Ended September 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net loss | |
$ | (13,424,460 | ) | |
$ | (11,112,604 | ) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 1,395,400 | | |
| 1,565,484 | |
Stock-based compensation | |
| 11,089,853 | | |
| 11,476,662 | |
Increase in bad debt reserve | |
| 478,086 | | |
| 132,727 | |
Changes in: | |
| | | |
| | |
Accounts receivable | |
| 838,453 | | |
| 6,854,150 | |
Prepaid expenses and other assets | |
| (728,030 | ) | |
| 2,199,333 | |
Accounts payable | |
| (858,820 | ) | |
| 393,817 | |
Revenue share payable | |
| (305,049 | ) | |
| (1,704,593 | ) |
Accrued expenses and other liabilities | |
| 508,548 | | |
| (1,237,689 | ) |
Deferred revenue | |
| 24,084 | | |
| (716,693 | ) |
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES | |
| (981,935 | ) | |
| 7,850,594 | |
| |
| | | |
| | |
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: | |
| | | |
| | |
Purchase of property and equipment | |
| (81,767 | ) | |
| (64,667 | ) |
Purchases of held-to-maturity investments | |
| (162,777,510 | ) | |
| (37,468,889 | ) |
Redemptions of held-to-maturity investments | |
| 165,088,755 | | |
| — | |
EvinceMed acquisition | |
| — | | |
| (2,000,000 | ) |
Acquisition of intangible assets, including intellectual property rights | |
| (3,796 | ) | |
| (158,321 | ) |
Capitalized software development costs | |
| (1,561,447 | ) | |
| — | |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | |
| 664,235 | | |
| (39,691,877 | ) |
| |
| | | |
| | |
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES: | |
| | | |
| | |
Cash paid for employee withholding taxes related to the vesting of restricted stock units | |
| (292,789 | ) | |
| — | |
Repurchase of common stock | |
| (7,522,426 | ) | |
| (12,561,571 | ) |
Proceeds from exercise of stock options | |
| 145,706 | | |
| 1,050,104 | |
Loan origination costs | |
| (300,000 | ) | |
| — | |
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES | |
| (7,969,509 | ) | |
| (11,511,467 | ) |
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | |
| (8,287,209 | ) | |
| (43,352,750 | ) |
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | |
| 18,208,685 | | |
| 84,681,770 | |
CASH AND CASH EQUIVALENTS - END OF PERIOD | |
$ | 9,921,475 | | |
$ | 41,329,020 | |
| |
| | | |
| | |
SUPPLEMENTAL CASH FLOW INFORMATION: | |
| | | |
| | |
Cash paid for interest | |
$ | — | | |
$ | — | |
Reduction of EvinceMed purchase price for amounts previously paid | |
$ | — | | |
$ | 708,334 | |
Shares issued in connection with acquisition | |
$ | — | | |
$ | 9,374,455 | |
Cash paid for income taxes | |
$ | — | | |
$ | — | |
The accompanying notes are an integral part of
these condensed consolidated financial statements.
OPTIMIZERX CORPORATION
RECONCILIATION of GAAP to NON-GAAP FINANCIAL
MEASURES
(UNAUDITED)
| |
Three Months Ended September 30, 2023 | | |
Nine months ended September 30, 2023 | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Net loss | |
$ | (2,865,297 | ) | |
$ | (3,466,792 | ) | |
$ | (13,424,460 | ) | |
$ | (11,112,604 | ) |
Depreciation, amortization and noncash lease expense | |
| 466,706 | | |
| 515,828 | | |
| 1,395,400 | | |
| 1,565,484 | |
Stock-based compensation | |
| 3,206,227 | | |
| 4,277,241 | | |
| 11,089,853 | | |
| 11,476,662 | |
Severance expense | |
| 206,477 | | |
| — | | |
| 206,477 | | |
| — | |
Acquisition expense | |
| 554,741 | | |
| — | | |
| 580,691 | | |
| 22,318 | |
Non-GAAP net income (loss) | |
| 1,568,854 | | |
| 1,326,277 | | |
| (152,039 | ) | |
| 1,951,860 | |
| |
| | | |
| | | |
| | | |
| | |
Non-GAAP net income (loss) per share | |
| | | |
| | | |
| | | |
| | |
Diluted | |
$ | 0.09 | | |
$ | 0.07 | | |
$ | (0.01 | ) | |
$ | 0.11 | |
Weighted average shares outstanding: | |
| | | |
| | | |
| | | |
| | |
Diluted | |
| 16,648,778 | | |
| 18,088,406 | | |
| 16,907,482 | | |
| 18,011,885 | |
| |
Three Months Ended
September 30, 2023 | | |
Nine months ended
September 30, 2023 | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Net loss | |
$ | (2,865,297 | ) | |
$ | (3,466,792 | ) | |
$ | (13,424,460 | ) | |
$ | (11,112,604 | ) |
Depreciation, amortization and noncash lease expense | |
| 466,706 | | |
| 515,828 | | |
| 1,395,400 | | |
| 1,565,484 | |
Stock-based compensation | |
| 3,206,227 | | |
| 4,277,241 | | |
| 11,089,853 | | |
| 11,476,662 | |
Severance expense | |
| 206,477 | | |
| — | | |
| 206,477 | | |
| — | |
Acquisition expense | |
| 554,741 | | |
| — | | |
| 580,691 | | |
| 22,318 | |
Interest income | |
| (688,190 | ) | |
| (289,967 | ) | |
| (2,074,081 | ) | |
| (313,786 | ) |
Adjusted EBITDA | |
| 880,664 | | |
| 1,036,310 | | |
| (2,226,120 | ) | |
| 1,638,074 | |
8
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Aug 2023 to Aug 2024